Development of Sensitization to Multiple Allergen Molecules from Preschool to School Age Is Related to Asthma

Anastasia Filiou, Idun Holmdahl, Anna Asarnoj, Marianne van Hage, Tina Ekenkrantz, Niclas Rydell, Anders Sjölander, Katarina Stenberg-Hammar, Gunilla Hedlin, Jon R. Konradsen, Cilla Söderhäll

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Astrid Lindgren’s Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Thermo Fisher Scientific, Uppsala, Sweden

Keywords
Allergen molecules · Allergic sensitization · Asthma · Longitudinal · Polysensitization · Preschool wheeze

Abstract
Introduction: Allergic sensitization in early life has been identified as a strong risk factor for subsequent asthma in childhood. It is still unclear why only a part of sensitized children develop asthma, and the role of specific allergen molecules in asthma pathogenesis is ambiguous [Pharmacol Ther. 2009 Feb;121(2):174–84]. We assessed the sensitization to multiple allergen molecules longitudinally and explored its relation to persistent asthma at 7 years. Methods: Seventy-two children included during an acute wheezing episode (cases) were followed prospectively from early preschool age (EPA) to age 7, and compared to 43 healthy controls at EPA. Allergen molecules were analyzed at EPA and age 7 using ImmunoCAP Solid-phase Allergen Chip (ISAC). Asthma diagnosis at 7 years was based on symptoms, medication, and spirometry. Results: At EPA, cases compared to controls showed a tendency toward having a higher prevalence of allergic sensitization (23.6% vs. 9.3%, p = 0.055). The prevalence of sensitization increased in cases from EPA to 7 years (23.6% vs. 38.9%; p = 0.048) as well as the median number (range) of immunoglobulin E (IgE)-reactive molecules 3 (3–14) versus 6.5 (1–21); p = 0.024. Sensitization to each additional molecule from EPA to the age of 7 was significantly related to asthma at 7 (OR = 1.25, 95% confidence interval [1.01, 1.54]). Conclusion: Polysensitization, assessed by allergen molecules, had a significant impact on persistent asthma at school age. The extent of sensitization, illustrated by molecular spreading from preschool to school age, was related to asthma diagnosis at 7 years in children with a history of wheezing at early life.

© 2022 The Author(s).
Published by S. Karger AG, Basel

Correspondence to:
Cilla Söderhäll, cilla.soderhall@ki.se
Introduction

Asthma is a highly heterogeneous disease, characterized by variable airflow obstruction, bronchial hyperresponsiveness, airway inflammation and in some cases airway remodeling [1]. The etiological mechanisms involved in the distinct phenotypical expressions of asthma constitute an issue of ambiguity.

Asthma is the most common chronic disease of childhood and is often preceded by respiratory illness with wheeze in preschool age [2]. Two-thirds of preschool wheezers outgrow their symptoms by the age of 6 years and the remaining third develop asthma [3–5]. Although the role of environmental and host-specific agents in asthma pathogenesis has been studied extensively, the factors that determine the persistence of asthma in later childhood remain unclear [2, 6, 7]. A number of epidemiological studies have shown a strong relationship between allergic sensitization and asthma [8–11]. Nevertheless, this relationship is inconsistent, and allergic sensitization seems to be neither necessary nor sufficient for the development of asthma [9, 12–15].

Allergic sensitization can be measured by skin prick tests or allergen-specific immunoglobulin E antibodies (IgE) in serum. IgE to either extract from whole allergen sources or to individual allergen molecules can be measured. The latter helps differentiate genuine sensitization against a certain allergen source from cross-reactivity due to homology between proteins from different allergen sources [16–18]. There are several techniques for molecular allergy diagnostics. ImmunoCAP Solid-phase Allergen Chip (ISAC) is a comprehensive platform composed of 112 micro-arrayed allergens and utilizes only minute amounts of serum [17, 19].

Sensitization to airborne or food allergens in early life has been identified as strong risk factors for subsequent asthma diagnosis in a number of cohort studies [20–24]. However, it remains unclear why only a part of sensitized children develop asthma and which allergen molecules are involved in the asthma pathogenesis at an early stage. There can be numerous sensitizing profiles and distinct combinations of allergen molecules that differ in their association with asthma [25–27]. Therefore, there is a need to further explore allergic sensitization on a molecular allergen level and clarify its impact on the onset and persistence of asthma.

The “Gene Expression in Wheezing and Asthmatic Children” (GEWAC) study started in 2008 and aimed to shed light on the complex etiology of preschool wheeze. Significant associations between subnormal levels of vitamin D [28], elevated chitinase-like protein (YKL-40) levels [29] as well as early infection with specific serotypes of RV [30] and acute wheeze have previously been shown in GEWAC cohort. In the current study, we assessed the sensitization profiles to a comprehensive panel of allergen molecules from early preschool age (EPA) to school age and studied their relation to persistent asthma at 7 years of age in the GEWAC cohort.

Materials and Methods

Study Design and Cohort

GEWAC is a longitudinal case-control study consisting of 156 cases and 102 age-matched healthy controls, as previously described [28, 29]. The cases (age 6–48 months) were enrolled at the pediatric emergency ward at Astrid Lindgren’s Children’s Hospital, Stockholm, Sweden, between 2008 and 2012 when presenting with acute wheeze. They came to a first revisit approximately 3 months later, and have been followed prospectively until 7 years of age. The age-matched controls were recruited from the surgical day-care ward during the same time period before going through minor surgery. The controls were assessed at inclusion, and at the age of 7 years. Inclusion and exclusion criteria are found in Table 1.

The study population of the current study comprises 72 cases and 43 controls. Sera for analyses of allergen molecules were collected both at the Early Preschool Age (EPA, sera available from either the time of inclusion [N = 7] or the first revisit [N = 65]) and at 7 years, when the children were also assessed regarding asthma.

Table 1. Inclusion and exclusion criteria, GEWAC study

| Cases (N = 156) | Inclusion criteria | Exclusion criteria |
|----------------|--------------------|-------------------|
| Age of 6–48 months | Acute symptoms of wheeze | Prematurity (birth before 36 gestational weeks) |
| Chronic disease | Simultaneous complications (e.g., sepsis, bacterial pneumonia) |

| Controls (N = 102) | Inclusion criteria | Exclusion criteria |
|-------------------|--------------------|-------------------|
| Age of 6–48 months | | Prematurity (birth before 36 gestational weeks) |
| History of bronchial obstruction and asthma or known sensitization to airborne allergens | |
diagnosis. Sera from the controls were available at the time of inclusion (N = 43/43) and at 7 years (N = 27/43) (Fig. 1).

**Sample Collection**

A standardized questionnaire regarding ethnicity, lifestyle, family history of asthma and allergies, breastfeeding, exposure to tobacco smoke, pets and previous infections, occurrence of atopic and asthmatic symptoms, use of asthma medication was filled out at the first revisit of cases and at inclusion of controls. Another standardized questionnaire regarding atopic symptoms as well as occurrence, frequency and duration of asthmatic symptoms and use of asthma medication during the preceding 12 months along with The Asthma Control Test (ACT) was filled out at the 7 years' follow-up.

**Blood samples** were collected from the cases and controls at each visit and analyzed at the laboratories of Clinical Chemistry, and of Clinical Immunology, Karolinska University Hospital, Stockholm Sweden. **Serum analysis** for 112 allergen molecules us-

---

**Fig. 1.** Flowchart GEWAC population included in the current study; the number of the cases and controls included in the different timepoints. The group of cases with available sera at the first revisit and at 7 years (n = 65) was merged with 7 cases that provided sera at the emergency visit and at 7 years. Accordingly, the first time-point of the longitudinal assessment of the cases is referred as the EPA. *Nasopharyngeal samples, **Complete Blood Counts.
Table 2. An overview of the main characteristics of the controls as well as the cases at EPA and the age of 7 years

| Variables at baseline (EPA)                                      | Controls (N = 43) | Cases (N = 72) at EPA |  | p value cases and controls at EPA | Cases without asthma at 7 years (N = 23) | Cases with asthma at 7 years (N = 49) |  | p value cases with and without asthma at age 7 |
|----------------------------------------------------------------|------------------|-----------------------|---|----------------------------------|------------------------------------------|----------------------------------------|---|-----------------------------|
| Age (mean value in months)                                      | 27               | 23                    | 0.027 |                                 | 20.5                                     | 24                                      | 0.14 |                             |
| Gender (male), % (N)                                            | 79.1 (34)        | 66.7 (48)             | 0.155 |                                 | 73.9 (17)                                | 63.3 (31)                              | 0.372 |                             |
| Heredity asthma, a % (N)                                        | 10.0 (4)         | 40.0 (28)             | 0.001 |                                 | 31.8 (7)                                 | 43.8 (21)                              | 0.344 |                             |
| Heredity atopy, a % (N)                                         | 55.0 (22)        | 72.9 (51)             | 0.057 |                                 | 68.2 (15)                                | 75.0 (36)                              | 0.552 |                             |
| Caucasian mother or father, a % (N)                            | 73.7 (28)        | 87.3 (62)             | 0.074 |                                 | 95.5 (21)                                | 83.7 (41)                              | 0.257 |                             |
| Exclusive breastfeeding at 4 months, a % (N)                    | 78.0 (32)        | 53.6 (37)             | 0.010 |                                 | 72.7 (16)                                | 44.7 (21)                              | 0.029 |                             |
| Smoking during pregnancy, a % (N)                              | 0.0 (0)          | 9.9 (7)               | 0.046 |                                 | 4.5 (1)                                  | 12.2 (6)                               | 0.423 |                             |
| Previous verified RSV infection, a % (N)                        | 2.4 (1)          | 25.4 (18)             | 0.002 |                                 | 27.3 (6)                                 | 24.5 (12)                              | 0.803 |                             |
| Allergic sensitization at EPA/inclusion, a % (N)                | 9.3 (1)          | 23.6 (17)             | 0.055 |                                 | 17.4 (4)                                 | 26.5 (13)                              | 0.395 |                             |
| Allergic sensitization in controls/cases aged <24 months at inclusion/EPA % (N) | 11.1 (2/18) | 15.2 (7/46) | 1.000 |                                 | 6.3 (1/16)                               | 20.0 (6/30)                            | 0.394 |                             |
| Allergic sensitization in controls/cases aged ≥24 months at inclusion/EPA, a % (N) | 8.0 (2/25) | 38.5 (10/26) | 0.010 |                                 | 42.9 (3/7)                               | 36.8 (7/19)                            | 1.000 |                             |
| Allergen molecules, n per sensitized individual, a; median value (range) | 1.5 (1–2) | 3 (1–14) | 0.082 |                                 | 1.5 (1–3)                               | 3 (1–14)                               | 0.079 |                             |
| Sensitization to ≥2 molecules, a % (N)                          | 4.6 (2)          | 18.1 (13)             | 0.039 |                                 | 8.7 (2)                                  | 22.4 (11)                              | 0.202 |                             |
| Total IgE (median values, kU/L)                                 | 183              | 24.51                 | 0.789 |                                 | 12.23                                   | 34.7                                   | 0.341 |                             |
| Airborne allergy symptoms, a % (N)                             | 0.0 (0)          | 5.6 (4)               | 0.295 |                                 | 0 (0)                                    | 8.2 (4)                                | 0.303 |                             |
| Food allergy symptoms, a % (N)                                 | 4.9 (2)          | 11.3 (8)              | 0.321 |                                 | 4.5 (1)                                  | 14.3 (7)                               | 0.420 |                             |
| Eczema, a % (N)                                                 | 7.3 (3)          | 21.1 (15)             | 0.055 |                                 | 18.2 (4)                                 | 22.4 (11)                              | 0.763 |                             |
| Variables at the age of 7 years                                 | Controls at the age of 7 years (N = 27) | Cases at the age of 7 years (N = 72) |  | p value cases and controls at 7 years | Cases without asthma at 7 years (N = 23) | Cases with asthma at 7 years (N = 49) |  | p value cases with and without asthma at age 7 |
| Allergic sensitization at 7, a % (N)                            | 22.2 (6)         | 38.9 (28)             | 0.120 |                                 | 26.1 (6)                                 | 22 (44.9%)                             | 0.127 |                             |
| Allergen molecules, n per sensitized individual, a; median value (range) at age 7 | 1.5 (1–7) | 63.1 (1–21) | 0.017 |                                 | 4 (1–7)                                  | 10.5 (1–21)                            | 0.059 |                             |
| Sensitization to ≥2 molecules at age 7, a % (N)                 | 11.1 (3)         | 33.3 (24)             | 0.027 |                                 | 17.4 (4)                                 | 40.8 (20)                              | 0.049 |                             |
| Airborne allergy symptoms at age 7, a % (N)                    | 0.0 (0)          | 18.1 (13)             | 0.017 |                                 | 0.0 (0)                                  | 26.5 (13)                              | 0.006 |                             |
| Food allergy symptoms at age 7, a % (N)                        | 3.7 (1)          | 11.1 (8)              | 0.437 |                                 | 0 (0)                                    | 16.3 (8)                               | 0.049 |                             |
| Eczema at age 7, a % (N)                                        | 3.7 (1)          | 9.7 (7)               | 0.441 |                                 | 0 (0)                                    | 14.3 (7)                               | 0.089 |                             |
| Asthma at the age of 7 years, a % (N)                           | 3.7 (1)          | 68.1 (49)             | <0.001 |                                 | 100 (23)                                 | 100 (49)                               | –     |                             |

p values for comparisons between cases and controls as well as between cases with and without asthma at the age of 7 years. RSV, respiratory syncytial virus. *69–71 cases/38–41 controls. bCases and controls having an allergen-specific IgE level ≥0.3 ISU against at least one allergen molecule.
Allergen Molecules and Childhood Asthma

Exposures and Outcomes

Heredity; history of asthma, eczema, inhalant, or food allergy in any of the parents or siblings. Heredity for atopy denotes history of at least one type of allergy or eczema in any of the parents or siblings.

Breastfeeding; exclusive breastfeeding during at least 4 months in infancy.

Tobacco smoke in utero; if the mother has smoked during pregnancy regardless of trimester.

Allergy symptoms; airborne allergy symptoms including rhinitis (sneezing, runny or blocked nose) and/or conjunctivitis, food allergy, and eczema (having dry skin in combination with a pruritic rash for at least 2 weeks) during the last 12 months as reported in the questionnaire at the respective revisit.

Allergic sensitization was defined as having an allergen-specific IgE level ≥0.3 ISU against at least one allergen molecule.

Asthma Definition

The definition of asthma at 7 years of age was based on Global Initiative for Asthma (GINA) guidelines [32] and included one mandatory criterion (a diagnosis of asthma by the study doctor, a pediatric allergist [KSH]) and 3 additional criteria: lower respiratory tract symptoms, medication for treatment of wheeze the preceding 12 months or airway reversibility >12% after the use of bronchodilator with salbutamol. Lower respiratory symptoms were defined as cough, shortness of breath, and nocturnal awakening caused by wheezing for 5 days or longer the preceding 12 months. All children that fulfilled the compulsory and at least one of the optional criteria (symptoms, medication or reversibility) were classified as having asthma.

Statistical Analyses

SPSS version 26 (IBM) was used. The prevalence of studied variables, expressed in percent of the total number of the available observations and the median number of positive IgE responses with ranges, were calculated for controls and cases at different timepoints. The median values of allergen molecule-specific IgE were calculated in groups of individuals sensitized to the respective molecule. 112 allergen molecules were ranked by prevalence and were calculated in groups of individuals sensitized to the respective molecule. 112 allergen molecules were ranked by prevalence and median value for each allergen molecule. The χ² test was used to analyse for significant proportional differences in categorical characteristics between 2 groups, and Fisher’s exact test was used on small sample sizes. An unpaired t test was used for numerical variables and a nonparametric test, Mann-Whitney, was used when assumptions for the unpaired t test were not met. p value <0.05 was considered significant. Odds ratios were calculated by univariate logistic regression and 95% confidence intervals (95% CI). Probability curves for asthma at 7 years of age based on the number of sensitizing allergen molecules (whichever of the 112 molecules) were derived from the results of a univariate logistic regression.

Results

Baseline Characteristics and Assessment of the Allergic Sensitization in Cases Compared to Controls at EPA

The study population consists of 72 cases who were assessed at EPA and age 7 as well as 43 controls investigated at EPA. No significant differences in demography, studied exposures, and atopic symptoms were observed between the 72 cases included and the 84 cases excluded from the current study population (online suppl. Table S1; see www.karger.com/doi/10.1159/000521324 for all online suppl. material). The included controls (N = 43) were significantly older (27 vs. 17 months, p < 0.001) and had a lower prevalence of heredity for asthma (10% vs. 27%, p = 0.037) than the excluded controls (N = 59) (online suppl. Table S1). Cases (N = 72) and controls (N = 43) differed significantly with respect to heredity for asthma, exposure to tobacco smoke during pregnancy, exclusive breastfeeding at 4 months, and previous Respiratory Syncytial Virus infections (Table 2). The controls had no knowledge of sensitization to airborne molecules which was a prerequisite for inclusion (Table 1).

At EPA, cases compared to controls showed a tendency toward having a higher prevalence of allergic sensitization (23.6% vs. 9.3%, p = 0.055) and being sensitized to a higher median number of molecules (3 [1–14] vs. 1.5 [1–2], p = 0.082, Table 2). Furthermore, sensitization to ≥2 molecules was noticed in a higher proportion of cases compared to controls (18.1% vs. 4.6%, p = 0.039). In total, sensitization against 37 different molecules was observed among cases, whereas the corresponding number in the controls was 6.

Longitudinal Assessment of Allergic Sensitization Profiles in the Preschool Wheezers (Cases)

Demography and data on exposure and serum analyses at EPA and 7 years in the 72 cases are demonstrated in Table 2. The prevalence of allergic sensitization increased from 23.6% at EPA to 38.9% at 7 years (p = 0.048, Table 2, shown in Fig. 2a). The median number of molecules with IgE reactivity in each sensitized case increased...
from 3 (1–14) at EPA to 6.5 (1–21) at age 7 (p = 0.024, Fig. 3a). The prevalence of sensitization to ≥2 molecules increased from 18.1% to 33% (p = 0.036) and the total number of allergen-specific IgE responses increased from 37 at EPA to 65 at age 7. Fifty-four percent (N = 39) of the cases were sensitized to the same number of molecules at EPA and age 7, whereas 39% (N = 28) were sensitized to more molecules and 7% (5) to fewer molecules at 7 years.

When applying combined ranking, the highest ranked molecule was Mal d 1 (apple) at EPA, and Bet v 1 (birch) at 7 years (online suppl. Tables S2, S3). Ara h 2 (peanut) and Bet v 1 were among the 3 highest ranked molecules at both timepoints (online suppl. Tables S2, S3). The prevalence of IgE reactivity to the most prevalent airborne molecules increased significantly from EPA to 7 years’ age (Bet v 1; 4.2% vs. 20.8%, p = 0.002, Fel d 1 [cat]; 2.8% vs. 13.9%, p = 0.016, Phil p 1 [timothy grass]; 0% vs. 19.4%, p < 0.001) whereas sensitization to peanut molecules (Ara h 1, Ara h 2, Ara h 3 and Ara h 6), developed at EPA, did not change significantly over time (p = 1.000, p = 1.000, p = 0.719, p = 1.000 respectively, Fig. 2a).

**Assessment of the Allergic Sensitization in the Preschool Wheezers at EPA in Relation to Asthma at 7 Years (Cases)**

The prevalence of asthma at the age of 7 years was 68.1% among the cases. Although no significant difference in the prevalence of allergic sensitization at EPA
was noticed between the groups of cases with and without asthma at 7 years (Table 2), sensitization to each additional molecule from EPA to the age of 7 was significantly related to asthma at 7 years (OR 1.25, 95% CI [1.01, 1.54], p = 0.04; Fig. 4a). Interestingly, the median number of molecules with IgE reactivity increased significantly from 3 (1–14) at EPA to 10.5 (1–21) at age 7, in each sensitized case with asthma at 7 years (p = 0.038, Table 2; Fig. 3b) whereas no significant change was noticed in cases without asthma at 7 years (p = 0.257, Table 2; Fig. 3b). Furthermore, a significantly greater increase in the number of IgE reactivities to allergen molecules from EPA to 7 years was noticed in cases sensitized against Ara h 2 (p = 0.003), Ara h 6 (p = 0.003), Bet v 1 (p = 0.042), or Fel d 1 (p = 0.033) at EPA compared to those not being sensitized against any of these molecules, which were among the highest ranked molecules at both time points (online suppl. Table S2). In addition, all children sensitized to ≥1 of the peanut molecules Ara h 1, Ara h 2, Ara h 3, and Ara h 6 at EPA (N = 7, 9.7%) received an asthma diagnosis at the age of 7 (p = 0.089, Fig. 2b, c).

Assessment of the Allergic Sensitization in the Preschool Wheezers at 7 Years and Its Relation to Asthma Diagnosis at 7 Years (Cases)

The prevalence of allergic sensitization at 7 years did not differ significantly between the asthma and the non-asthma group at 7 years (p = 0.127, Table 2). However, the prevalence of sensitization to Bet v 1 (20.8%) at 7 years was significantly higher among the cases with asthma than those without asthma (N = 14 [28.6%] vs. N = 1 (4.3%), p = 0.027, online suppl. Table S3; Fig. 2b, c). Moreover, the number of sensitizing molecules in each case at 7 years (6.5 [1–21]) was significantly associated to asthma at the same age (OR 1.20, 95% CI [1.02, 1.42], p = 0.043; Fig. 4b). Notably, the cases with sensitization to ≥6 molecules at 7 years (N = 15, 20.8%) were more likely to have asthma (p = 0.027, OR = 8.80, 95% CI [1.08, 71.70]) than those sensitized to <6 molecules.

Discussion

In the cross-sectional part of our study, the prevalence of sensitization to ≥2 molecules at EPA was significantly higher in children with preschool wheezing compared to the healthy controls. The longitudinal approach focused
Fig. 4. **a** The difference in the number of allergen molecules with IgE reactivity per individual between EPA and the age of 7 and probability for asthma at 7 years. OR 1.248, 95% CI (1.011–1.540), $p = 0.039$; calculated by logistic regression in cases ($N = 72$). **b** The number of allergen molecules with IgE reactivity per individual at 7 years and probability for asthma at 7 years. OR 1.195, 95% CI (1.006–1.419), $p = 0.043$; calculated by logistic regression in cases ($N = 72$).
on the assessment of the sensitization profiles in children with a history of wheezing at preschool age, their development over time and subsequent risk for asthma at school age. Using the comprehensive ISAC platform, we noticed that the number of sensitizing allergen molecules increased over time in cases. Furthermore, the range and the median number of molecules with IgE reactivity increased from EPA to 7 years. Interestingly, sensitization to each additional molecule from EPA to the age of 7 was significantly related to asthma at 7 years. Finally, sensitization to Bet v 1 and the number of sensitizing molecules at 7 years were significantly associated to asthma diagnosis at the same age.

Our main findings suggest that polysensitization, captured by molecular allergy diagnostics, has a crucial impact on both preschool wheezing and persistent asthma at school age, both cross-sectionally and longitudinally. Our results comply with previous reports regarding the effect of early polysensitization on allergic multimorbidity including wheezing as early as at 2 years of age [42, 43]. Extract-based testing in cohorts of preschool wheezers has shown early polysensitization to be linked to persistent asthma at school age [42, 44, 45]. In addition, studies are pointing to the advantages of molecular allergy testing when assessing the allergic sensitization, particularly for polysensitized individuals [46] and the subsequent risk for atopic disease including asthma [25, 26, 47]. Our results regarding association between the median number of molecules with IgE reactivity at 7 years and asthma at the same age are in line with another cross-sectional study, which showed that children with asthma at 11 years were sensitized to significantly more allergen molecules at the same age than children without asthma [26]. Moreover, 2 cross-sectional Swedish studies underline the role of polysensitization by showing that the number of sensitizing dog allergen molecules was significantly related to the risk for reported asthma [48] and that sensitization to multiple lipocalin components was associated to severe asthma [49].

According to our results (online suppl. Table S2), no significant association between sensitization against any of the highest ranked molecules at EPA and asthma at 7 years was found. The age at inclusion in our study ranged from 6 months to 4 years with 36% (26/72) of cases being ≥24 months old when tested for allergic sensitization. Due to small sample of children being younger, the impact of sensitization below 2 years of age on later asthma development could not be clarified. Nevertheless, sensitization to Bet v 1 at 7 years was shown to be significantly associated to asthma at the same age (online suppl. Table S3). There is conflicting evidence about the role of sensitization to specific allergen molecules in asthma development. On the one hand, a study by Fontanella et al. [26] suggests that the pattern of interactions between molecule-specific IgE responses within each cluster of allergen molecules may predict asthma rather than the single molecule-specific IgE reactivity. On the other hand, several other studies have shown that sensitization to specific allergen molecules has a significant association as well as a predictive value for asthma [34, 50]. The identified “high-risk” allergen molecules comprise perennial allergens such as allergen molecules from pets [51], house dust mites [52], as well as pollens, and foods [34].

Using molecular diagnostics, we have demonstrated the development of molecular spreading among the children with a history of preschool wheezing in relation to the probability of persistent asthma at the age of 7. Howard et al. [18] have shown that the number of sensitizing
allergen molecules increases across different age points in childhood. However, it is still unclear how the molecular spreading influences the atopic march in the growing child. Longitudinal studies have shown that the initial IgE reactivity to a group of initiator allergen molecules may stay mono-molecular or expand to an oligo- or even poly-molecular stages [52, 53]. Our findings suggest that Bet v 1, Ara h 2, and Ara h 6, and Fel d 1 (cat) may have served as “initiator” molecules, triggering molecular spreading from EPA to school age and thereby affecting the development of persistent asthma at the age of 7 years.

Among the strengths of our study are the prospective design and the two-dimensional approach that allowed multiple comparisons between children suffering from acute wheeze and healthy controls, cross-sectionally and longitudinally. This approach enabled the assessment of allergic sensitization at different age points and its impact on two main clinical outcomes, preschool wheezing and persistent asthma at the age of 7. To our knowledge, this study is one of few studies which assess allergic sensitization longitudinally, from early childhood to school age, using analyses of 112 allergen molecules. Another asset was that the asthma diagnosis was according to the GINA guidelines and judged by the same pediatric allergologist. The included lung function measurements are objective parameters contributing to high internal validity.

Because of the size of our study population, we had limited statistical power to adjust for potential confounders or even detect effect modification by these factors. Our sample size was restricted by the availability of sera which potentially introduced selection bias. This is reflected in the age difference between the case and the control group, with the group of cases being slightly younger than the controls, which derived from the original age-matched groups. Furthermore, the measures of allergic sensitization in controls might be underestimated and the observed differences from the case group might be over-estimated since known sensitization to airborne allergens at EPA was an exclusion criterion for the control group. Moreover, the use of standardized questionnaires filled out at the revisits to report symptoms and medication during a year may have introduced recall bias. As mentioned above, the features of the GEWAC cohort at inclusion indicate its high-risk nature which limits the external validity of this study. Nevertheless, zooming in the molecular sensitization profiles in a selected population with predominantly severe preschool wheeze makes this study unique in the field.

Conclusion

Polysensitization assessed on a molecular allergen level has a significant impact on both early-life wheezing and persistent asthma at school age. The notion of molecular spreading from preschool to school age is apparent and seems to contribute significantly to the risk for asthma at the age of 7 years in individuals with a history of wheezing in early life. Our results point to Bet v 1, Ara h 2, and Ara h 6, and Fel d 1 as potential markers of molecular spreading through which they may affect the course of asthma disease. Future research is warranted to shed light on “high risk” allergen molecules or sensitization profiles that may pave the way for novel prevention and therapeutic strategies.

Acknowledgments

We would like to thank all the participating children and their parents/legal guardians for making this study possible. We also thank Ann Berglind for valuable assistance in collecting data and biological sampling.

Statement of Ethics

This study has ethical approval from the Regional Ethics Committee at Karolinska Institutet, Stockholm (Dnr 2008/378-31/4 and Dnr 2014/399-31/3). Written and oral information about the study was provided to the parents, and written consent was obtained from parents and/or legal guardians prior to the study.

Conflict of Interest Statement

Anastasia Eleni Filiou, Idun Holmdahl, Anna Asarnoj, Katariina Stenberg-Hammar, and Gunilla Hedlin have no conflicts of interest to declare. Marianne van Hage reports personal fees from Thermo Fisher Scientific, outside the submitted work. Niclas Rydell, Tina Ekencrantz, and Anders Sjölander are employees of Thermo Fisher Scientific. Dr Konradsen and Dr. Söderhäll report nonfinancial support from Thermo Fisher Scientific, during the conduct of the study.

Funding Sources

This work was financially supported by The Swedish Research Council, the Swedish Heart–Lung Foundation, Karolinska Institutet, Konsul Th C Bergh Foundation, Freemason Child House Foundation in Stockholm, the Centre for Allergy Research at Karolinska Institutet, the Samaritan Foundation, Sigurd and Elsa
Allergen Molecules and Childhood Asthma

Author Contributions

A.F., J.R.K., C.S., G.H., and K.S.-H. analyzed the data and performed statistical analyses. All authors were involved in data interpretation. A.F., J.R.K., and C.S. drafted the manuscript. All authors critically evaluated and revised the final manuscript.

Data Availability Statement

Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.

References

1. Rådinger M, Lötvall J. Eosinophil progenitors in allergy and asthma: do they matter? Pharmacol Ther. 2009 Feb;121(2):174–84.
2. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008 Oct 1;178(7):667–72.
3. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995 Jan 19;332(3):133–8.
4. Sherriff A, Peters TJ, Henderson J, Strachan DP. Risk factor associations with wheezing patterns in children followed longitudinally from birth to 3(1/2) years. Int J Epidemiol. 2001 Dec;30(6):1473–84.
5. Matricardi PM, Illi S, Gruber C, Keil T, nickel R, Wahn U, et al. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. Eur Respir J. 2008 Sep;32(3):585–92.
6. Ducharme FM, Tse SM, Chiazza B. Diagnosis, management, and prognosis of preschool wheeze. Lancet. 2014 May 3;383(9928):1593–604.
7. Loss GJ, Depner M, Hose AJ, Genuneit J, Karvonnen AM, Hyvarinen A, et al. The early development of wheeze. Environmental determinants and genetic susceptibility at 17q21. Am J Respir Crit Care Med. 2016 Apr 15;193(8):889–97.
8. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989 Feb 2;320(5):271–7.
9. Pearce N, Pekkanen J, Beasley R. How much loss GJ, Depner M, Hose AJ, Genuneit J, Karlsson AM, Hyvärinen A, et al. The early development of wheeze. Environmental determinants and genetic susceptibility at 17q21. Am J Respir Crit Care Med. 2016 Apr 15;193(8):889–97.
10. Toskala E, Kennedy DW. Asthma risk factors. Int Forum Allergy Rhinol. 2015 Sep;5 Suppl 1(Suppl 1):S11–6.
11. Bloom CI, Franklin G, Bush A, Saglani S, Quint JK. Burden of preschool wheeze and progression to asthma in the UK: population-based cohort 2007 to 2017. J Allergy Clin Immunol. 2021 May;147(5):1949–58.
12. Kurukulaarachchi RJ, Fenn MH, Waterhouse LM, Matthews SM, Holgate ST, Arshad SH. Characterization of wheezing phenotypes in the first 10 years of life. Clin Exp Allergy. 2003 May;33(5):573–8.
13. Weinmayr G, Weiland SK, Björkstén B, Brunekreef B, Büchele G, Cookson WO, et al. Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med. 2007 Sep 15;176(6):656–75.
14. Ballardini N, Bergström A, Wahlgren CF, van Hage M, Halinder E, Kull I, et al. IgE antibodies in relation to prevalence and multimorbidity of eczema, asthma, and rhinitis from birth to adolescence. Allergy. 2016 Mar;71(3):342–9.
15. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018 Feb 24;391(10122):783–800.
16. Konradsen JR, Nordlund B, Onell A, Borres M, Grönblad H, Hedlin G. Severe childhood asthma and allergy to fruits: refined assessment using molecular-based allergy diagnostics. Pediatr Allergy Immunol. 2014 Mar;25(2):187–92.
17. Prosperi MC, Belgrave D, Buchan I, Simpson A, Custovic A. Challenges in interpreting allergen microarrays in relation to clinical symptoms: a machine learning approach. Pediatr Allergy Immunol. 2014 Feb;25(1):71–9.
18. Howard R, Belgrave D, Papastamoulis P, Simpson A, Rattray M, Custovic A. Evolution of IgE responses to multiple allergen components and their relevance to atopic diseases in children aged 6 years: results of the GINI study. J Invest Allergol Clin Immunol. 2009;19(3):180–7.
19. Alduraywish SA, Standl M, Lodge CJ, Abramson MJ, Allen KJ, Erbas B, et al. Is there a march from early food sensitization to later childhood allergic airway disease? Results from two prospective birth cohort studies. Pediatr Allergy Immunol. 2017 Feb;28(1):30–7.
20. Bao Y, Chen Z, Liu E, Xiang L, Zhao D, Hong J. Risk factors in preschool children for predicting asthma during the preschool age and the early school age: a systematic review and meta-analysis. Curr Allergy Asthma Rep. 2017 Nov 18;17(12):85.
21. Rodríguez-Martínez CE, Sossa-Bricheo MP, Castro-Rodriguez JA. Factors predicting persistence of early wheezing through childhood and adolescence: a systematic review of the literature. J Asthma Allergy. 2017;10:83–98.
22. Vermeulen EM, Koplin JJ, Dharmage SC, Gurrin LC, Peters RI, McWilliam V, et al. Food allergy is an important risk factor for childhood asthma, irrespective of whether it resolves. J Allergy Clin Immunol Pract. 2018 Jul–Aug;6(4):1336–41.e3.
23. Simpson A, Lazic N, Belgrade DC, Johnson P, Bishop C, Mills C, et al. Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years. J Allergy Clin Immunol. 2015 Nov;136(5):1224–31.
24. Fontanella S, Frainay C, Murray CS, Simpson A, Custovic A. Machine learning to identify pairwise interactions between specific IgE antibodies and their association with asthma: a cross-sectional analysis within a population-based birth cohort. PLoS Med. 2018 Nov;15(11):e1002691.
25. Roberts G, Fontanella S, Selby A, Howard R, Filippi S, Hedlin G, et al. Connectivity patterns between multiple allergen specific IgE antibodies and their association with severe asthma. J Allergy Clin Immunol. 2020 Oct;146(4):821–30.
26. Stenberg Hammar K, Hedlin G, Konradsen JR, Nordlund B, Kull I, Giske CG, et al. Sub-normal levels of vitamin D are associated with acute wheeze in young children. Acta Paediatr. 2014 Aug;103(8):856–61.
In a longitudinal assessment of circulating YKL-40 levels in preschool children with wheeze, Pediatr Allergy Immunol. 2017 Feb; 28(1):79–85.

Severe episodic viral symptoms. Allergy. 2016 Dec; 71(12):1728–35.

Severity of obstructive airways disease by age 2 years predicts asthma at 10 years of age. Thorax. 2008 Jan; 63(1):8–13.

Prevalence of allergy and asthma in a rural population of preschool children. Pediatr Allergy Immunol. 2013 Sep; 24(6):549–55.

Detection of IgE reactivity to a handful of allergen molecules in early childhood predicts respiratory allergy in adolescence. EbioMedicine. 2017 Dec; 26:91–9.

Wickman M, Lupinec C, Andersson N, Belgrave D, Asarnoj A, Benet M, et al. Detection of IgE reactivity to a handful of allergen molecules in early childhood predicts respiratory allergy in adolescence. EbioMedicine. 2017 Dec; 26:91–9.

Ginet Initiative for Asthma. Global strategy for asthma management and prevention; 2021. p. 19–30. Available from: http://gin-asthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf

Nissen SP, Kjaer HF, Høst A, Nielsen J, Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug; 26(2):319–38.

A longitudinal assessment of circulating YKL-40 levels in preschool children with wheeze. Pediatr Allergy Immunol. 2017 Feb; 28(1):79–85.

Severe episodic viral symptoms. Allergy. 2016 Dec; 71(12):1728–35.

Severity of obstructive airways disease by age 2 years predicts asthma at 10 years of age. Thorax. 2008 Jan; 63(1):8–13.

Prevalence of allergy and asthma in a rural population of preschool children. Pediatr Allergy Immunol. 2013 Sep; 24(6):549–55.

Ginet Initiative for Asthma. Global strategy for asthma management and prevention; 2021. p. 19–30. Available from: http://gin-asthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf

Nissen SP, Kjaer HF, Høst A, Nielsen J, Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug; 26(2):319–38.

Ginet Initiative for Asthma. Global strategy for asthma management and prevention; 2021. p. 19–30. Available from: http://gin-asthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf

Nissen SP, Kjaer HF, Høst A, Nielsen J, Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug; 26(2):319–38.

Ginet Initiative for Asthma. Global strategy for asthma management and prevention; 2021. p. 19–30. Available from: http://gin-asthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf

Nissen SP, Kjaer HF, Høst A, Nielsen J, Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug; 26(2):319–38.

Ginet Initiative for Asthma. Global strategy for asthma management and prevention; 2021. p. 19–30. Available from: http://gin-asthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf

Nissen SP, Kjaer HF, Høst A, Nielsen J, Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug; 26(2):319–38.

Ginet Initiative for Asthma. Global strategy for asthma management and prevention; 2021. p. 19–30. Available from: http://gin-asthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf

Nissen SP, Kjaer HF, Høst A, Nielsen J, Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug; 26(2):319–38.

Ginet Initiative for Asthma. Global strategy for asthma management and prevention; 2021. p. 19–30. Available from: http://gin-asthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf

Nissen SP, Kjaer HF, Høst A, Nielsen J, Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug; 26(2):319–38.